Ipca Laboratories to Close Mahad Plant and Sell Leasehold Property to ICMC Corporation Ltd. for Rs.16.90 Crores
Closure of Mahad drug intermediates unit will not impact business; sale completion expected by March 31, 2027 subject to approvals
Ipca Laboratories Limited announces closure of its drug intermediates manufacturing unit in Mahad, Maharashtra, and sale of the associated leasehold land and buildings to ICMC Corporation Ltd. for Rs.16.90 crores. The move is part of operational strategy to consolidate manufacturing operations without impacting business or financials, with activities shifted to other units and transaction expected to complete by March 31, 2027.
Ipca Laboratories Limited
Capacity Expansion
Ipca Laboratories Limited announced the closure of its drug intermediates manufacturing unit located at Mahad, Maharashtra, and plans to sell the associated leasehold land and factory buildings to ICMC Corporation Ltd. for Rs.16.90 crores as part of its manufacturing optimization strategy.
The Mahad manufacturing unit covers leasehold land measuring approximately 25,138 square meters with old factory buildings totaling about 11,913 square meters.
Plant machineries will be transferred to other Ipca manufacturing units, and the drug intermediates production has already been moved accordingly, ensuring no disruption to company operations or financials.
The sale agreement was entered into on November 20, 2026, with completion expected on or before March 31, 2027, subject to necessary approvals from MIDC and other consents.
ICMC Corporation Ltd., the buyer, is a company engaged in the development and sale of micro-nutrient fertilizers and is not related to Ipca Laboratories or its promoters.
This transaction is a strategic move outside any scheme of arrangement and complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, specifically Regulation 37A.
Highlights
- Closure of Mahad drug intermediates manufacturing unit as part of operational consolidation.
- Leasehold land and buildings covering over 25,000 sq. meters sold for Rs.16.90 crores.
- Machinery relocated to other Ipca manufacturing units; no impact on business or financials.
- Sale agreement signed November 20, 2026; expected to complete by March 31, 2027.
- Buyer ICMC Corporation Ltd. is independent and not related party to Ipca Laboratories.
Key Data Snapshot
What happened
- Ipca Laboratories decided to close and sell its drug intermediates manufacturing unit located in Mahad, Maharashtra.
- The associated leasehold land and old factory buildings will be sold to ICMC Corporation Ltd. for Rs.16.90 crores.
- This initiative is part of optimizing manufacturing facilities by reducing the number of smaller units.
Key details
- The Mahad unit’s land measures 25,138 square meters with factory buildings covering 11,913 square meters.
- Plant machinery will be transferred to other Ipca units; drug intermediates manufacturing has been moved accordingly.
- The transaction was formalized with an MOU on November 20, 2026, and final deed execution awaits regulatory approvals.
- Sale proceeds will be paid via bank transfer; transaction is outside any scheme of arrangement.
- Buyer is an independent fertilizer company not related to Ipca Laboratories or its promoters.
Strategic context
- The closure and sale support Ipca Laboratories’ strategic effort to consolidate and optimize its manufacturing footprint.
- There will be no impact on the company’s business operations or financial results as production has shifted to other manufacturing units.
Regulatory and governance context
- Transaction complies with SEBI (LODR) Regulation 37A requirements and is outside the scope of any arrangement schemes.
- Necessary approvals from Maharashtra Industrial Development Corporation (MIDC) and other consents are pending for leasehold land transfer.
Highlights
- Closure of Mahad drug intermediates manufacturing unit as part of operational consolidation.
- Leasehold land and buildings covering over 25,000 sq. meters sold for Rs.16.90 crores.
- Machinery relocated to other Ipca manufacturing units; no impact on business or financials.
- Sale agreement signed November 20, 2026; expected to complete by March 31, 2027.
- Buyer ICMC Corporation Ltd. is independent and not related party to Ipca Laboratories.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30 and Regulation 37A
More News on Capacity Expansion
View allLatest corporate announcements and market updates in Capacity Expansion.
Dhunseri Ventures Subsidiary Starts Trial Production at Kathua BOPP Plant, Second Line to Launch by March 2027
Dhunseri Ventures Limited announced that its subsidiary Dhunseri Poly Films Private Limited has commenced trial production at its BOPP plant located in Kathua, Jammu. Commercial production will begin once acceptance criteria are met and protocols finalized.
Read Full StoryACME Solar Holdings Commissions Additional 16.06 MW/69.678 MWh Battery Energy Storage Capacity at Rajasthan Project
ACME Solar Holdings Limited has commissioned an additional 16.06 MW / 69.678 MWh discharge capacity of its Battery Energy Storage System through its subsidiary at the FDRE project in Rajasthan, increasing its total commissioned capacity to 175.72 MW / 733.939 MWh as of November 20, 2026, with commercial operations beginning November 22, 2026.
Read Full StoryACME Solar Holdings Commissions 35.81 MW Battery Energy Storage System at Tata FDRE Power Project
ACME Solar Holdings Limited, through its wholly-owned subsidiary ACME Sigma Urja Private Limited, has commissioned 35.81 MW of the Battery Energy Storage System at the Tata FDRE Power Project in Rajasthan as of November 20, 2026.
Read Full Story